Coleman CI, et al. - A propensity-score weighted administrative claims cohort study was performed to investigate the effectiveness and safety of rivaroxaban vs warfarin in patients with unprovoked venous thromboembolism (VTE). Adults with a primary diagnosis of VTE newly-initiated on rivaroxaban or warfarin within 30-days of the incident VTE and with ≥12-months of continuous insurance benefits prior to the VTE (baseline) were included in a retrospective claims data analysis using US MarketScan claims from 1/2012 to 12/2016. Ten thousand, four hundred eighty-nine rivaroxaban users and 26,364 warfarin users with incident unprovoked VTE were identified. Results of this study suggested that rivaroxaban had the potential to reduce both the risk of major bleeding and recurrent VTE compared to warfarin in patients with unprovoked VTE.